One challenge is the inconsistent and inconclusive evidence, with some studies reporting significant expression levels, while others find lower levels due to variations in patient populations, tumor heterogeneity, and differences in laboratory techniques used to assess PD-1/PD-L1 expression. Here, CD274 is linked to neoplasm.